# DESCRIPTION

## BACKGROUND

- introduce nitric oxide synthases (NOSs)
- describe function of NO in mammalian systems
- discuss isoforms of NOS
- motivate selective inhibition of nNOS
- limitations of existing nNOS inhibitors

## SUMMARY

- introduce disclosed compounds and compositions
- describe method of using disclosed compounds
- motivate selective inhibition of nNOS
- describe advantages over prior art
- define formula for disclosed compounds
- describe potential applications of disclosed compounds

## DETAILED DESCRIPTION

- define terms
- specify meaning of "a", "an", and "the"
- define "about", "approximately", "substantially", and "significantly"
- define "include" and "including"
- define "comprise" and "comprising"
- define "consist" and "consisting of"
- define "consisting essentially of"
- define "subject in need thereof"
- introduce chemical entities
- define "alkyl"
- define "alkylene"
- define "haloalkyl"
- define "heteroalkyl"
- define "alkenyl"
- define "alkynyl"
- define "cycloalkyl"
- define "cycloalkylene"
- define "partially unsaturated carbocyclyl"
- define "aryl"
- define "heterocyclyl" and "heterocyclic group"
- define "heteraryl"
- define subject
- describe nitric oxide synthase activity
- introduce effective amount
- define modulate
- describe method of inhibiting nitric oxide synthase
- describe pharmaceutical composition
- describe contacting nitric oxide synthase
- describe inhibition of nitric oxide synthase
- describe dosage amount
- describe pharmaceutical formulation
- describe medicament administration
- introduce novel 7-phenyl-2-aminoquinolines
- describe compounds and pharmaceutical compositions
- describe method of treating disease or disorder
- describe formula of compounds
- describe X substituents
- describe specific compounds
- describe alkyl-amino substituted phenyl compounds
- describe alkyl-amino substituted pyridyl compounds
- describe isoindolinyl compounds
- describe amino-substituted indanyl compounds
- describe pharmaceutical compositions
- describe method of treating disease or disorder
- describe method of inhibiting nitric oxide synthase
- describe method of inhibiting neuronal nitric oxide synthase

### ILLUSTRATIVE EMBODIMENTS

- define compound of formula
- specify X in formula
- specify substituents of X
- define embodiment 2
- specify X in embodiment 2
- specify substituents of X in embodiment 2
- define embodiment 3
- specify Z in embodiment 3
- define embodiment 4
- specify R in embodiment 4
- specify substituents of R
- define embodiment 5
- specify Z in embodiment 5
- define embodiment 6
- define embodiment 7
- specify X in embodiment 7
- specify substituents of X in embodiment 7
- define embodiment 8
- define embodiment 9
- define embodiment 10
- specify X in embodiment 10
- define embodiment 11
- define embodiment 12
- specify X in embodiment 12
- define embodiment 13
- define embodiment 14
- define pharmaceutical composition
- define embodiment 15
- specify disease or disorder
- define embodiment 16
- specify disease or disorder
- define embodiment 17
- define embodiment 18
- define embodiment 19-23
- synthesize derivatives 49
- synthesize derivatives 10/11 and 12/13
- perform Suzuki coupling
- deprotect derivatives 58-66
- synthesize derivative 14
- synthesize derivative 15
- synthesize derivative 16
- synthesize derivatives 17 and 18
- synthesize derivatives 19-24
- prepare 4-ether halide derivatives 25-37
- perform Suzuki coupling with 39
- deprotect derivatives 117-135
- determine inhibitory constants
- perform crystallography
- analyze initial inhibitory and structural data
- discuss X-ray crystal structure of 5 bound to rnNOS, hnNOS, and heNOS
- discuss binding of 5 in heNOS
- optimize conformational positioning of the tail amine of 5
- discuss X-ray crystal structures of 7 bound to rnNOS and hnNOS
- compare SAR of phenylaminoquinoline and phenyl ether compounds
- discuss distinct parts of the SAR
- describe o-substituted isomers
- compare potency of o-substituted isomers
- describe m-substituted isomers
- compare potency of m-substituted isomers
- analyze kinetic data for 12
- describe X-ray crystal structures of rnNOS-12 and hnNOS-12
- analyze binding interactions of 12
- contrast binding interactions of 12 with heNOS-12
- propose homologated analogue 13
- analyze nNOS inhibitory activity of 13
- describe crystal structures of rnNOS-13 and hnNOS-13
- analyze binding interactions of 13
- discuss installation of nitrile at 5-position
- analyze potency of 14
- describe crystal structure of 12
- propose pyridine 15
- analyze potency of 15
- describe constrained amine analogues 16-18
- describe 4-alkoxy-3-aminomethyl analogues 19-29
- analyze potency of 24
- describe crystal structure of 24 bound to rnNOS
- discuss further improvement for rnNOS inhibition
- describe illustrative embodiments
- introduce inhibitors 32 and 33
- motivate pyridinylmethyl ether groups
- discuss rnNOS potency of 32 and 33
- analyze crystal structure of rnNOS-32
- compare binding positions of 32 and 33
- discuss differences in binding to rnNOS and hnNOS
- explain decreased binding affinity of 32 to hnNOS
- discuss selectivities of 32
- compare 32 to previously reported aminoquinolines
- discuss heNOS-32 crystal structure
- explain good hn/heNOS selectivity of 32
- introduce inhibitor 33
- discuss hnNOS potency of 33
- analyze X-ray structure of hnNOS-33
- discuss binding to rnNOS and hnNOS
- explain equal potency of 33 against rat and human enzymes
- discuss heNOS-33 crystal structure
- explain 3-fold improvement in binding affinity of 33
- discuss human iNOS inhibition study
- illustrate inhibitor selectivity
- discuss limitations of static X-ray structures
- introduce off-target profiling
- describe radioligand displacement assay
- classify off-target binding
- discuss off-target profiles of aminoquinolines
- introduce membrane permeability and microsome stability
- describe PAMPA-BBB assay
- discuss permeability results
- introduce SwissADME predictive model
- discuss microsome stability results
- summarize conclusions
- introduce novel 7-phenyl-2-aminoquinolines
- discuss modifications to 12
- discuss crystal structures
- discuss mutagenesis studies
- discuss selectivity of inhibitors
- introduce experimental section
- describe general procedures
- describe Suzuki coupling
- describe deprotection of aminoquinolines
- describe preparation of quinoline precursors
- describe assembly of final compounds
- describe preparation of other precursors
- describe General Procedure 1
- describe General Procedure 2
- describe purification of compounds
- describe workup of compounds
- describe characterization of compounds
- describe HRMS data
- describe NMR data
- synthesize compound 8
- characterize compound 8
- synthesize compound 9
- characterize compound 9
- synthesize compound 10
- characterize compound 10
- synthesize compound 11
- characterize compound 11
- synthesize compound 12
- characterize compound 12
- synthesize compound 13
- characterize compound 13
- describe general procedure 1
- describe general procedure 2
- provide experimental conditions
- report analytical data
- describe compound 14
- provide NMR and HRMS data for compound 14
- describe compound 15
- provide NMR and HRMS data for compound 15
- describe compound 16
- provide NMR and HRMS data for compound 16
- describe compound 17
- provide NMR and HRMS data for compound 17
- describe compound 18
- provide NMR and HRMS data for compound 18
- describe compound 19
- provide NMR and HRMS data for compound 19
- detail general procedure 1
- detail general procedure 2
- describe purification by flash column chromatography
- describe treatment with methanolic HCl
- describe precipitation and drying of compounds
- describe compound 20
- describe compound 21
- describe compound 22
- describe compound 23
- describe compound 24
- describe compound 25
- synthesize compound 20
- synthesize compound 21
- synthesize compound 22
- synthesize compound 23
- synthesize compound 24
- synthesize compound 25
- characterize compound 20
- characterize compound 21
- characterize compound 22
- characterize compound 23
- characterize compound 24 and 25
- describe compound 26
- describe compound 27
- describe compound 28
- describe compound 29
- describe compound 30
- describe compound 31
- synthesize compound 26
- synthesize compound 27
- synthesize compound 28
- synthesize compound 29
- synthesize compound 30
- synthesize compound 31
- characterize compound 26
- characterize compound 27
- characterize compound 28
- characterize compound 29
- characterize compound 30
- characterize compound 31
- purify compound 26
- purify compound 31
- describe compound 32
- describe synthesis of compound 32
- describe characterization of compound 32
- describe compound 33
- describe synthesis of compound 33
- describe characterization of compound 33
- describe compound 34
- describe synthesis of compound 34
- describe characterization of compound 34
- describe compound 35
- describe synthesis of compound 35
- describe characterization of compound 35
- describe compound 36
- describe synthesis of compound 36
- describe characterization of compound 36
- describe compound 37
- describe synthesis of compound 37
- describe characterization of compound 37
- provide general procedure 1
- provide general procedure 2
- provide additional experimental details
- synthesize compound 39
- describe NMR spectra of compound 39
- introduce NOS enzyme assays
- describe hemoglobin capture assay
- outline experimental conditions for NOS enzyme assays
- calculate IC50 and Ki values
- introduce PAMPA-BBB assay
- describe experimental conditions for PAMPA-BBB assay
- calculate effective permeability
- define retention membrane factor
- provide equations for Pe and R calculations
- describe human liver microsome stability assay
- calculate half-life and intrinsic clearance
- prepare inhibitor complex crystals
- grow crystals using sitting drop vapor diffusion method
- soak crystals with inhibitor
- collect X-ray diffraction data
- process and refine X-ray diffraction data
- detect inhibitor binding using difference Fourier maps
- model and refine inhibitor structures
- validate and deposit refined structures
- list PDB ID codes
- list references
- cite neurodegenerative disorders research
- cite neurodegenerative disorders research
- cite neurodegenerative disorders research
- cite nitric oxide synthase research
- cite nitric oxide synthase research
- cite neuronal nitric oxide synthase inhibitors
- cite neuronal nitric oxide synthase inhibitors
- cite neuronal nitric oxide synthase inhibitors
- cite neuronal nitric oxide synthase inhibitors
- cite tuberculosis research
- cite mycobacterial dihydrofolate reductase inhibitors
- cite neuronal nitric oxide synthase inhibitors
- cite indazoles patent
- cite asymmetric synthesis of amines
- cite pyridinonyl pdk1 inhibitors patent
- cite halogenalkyl-substituted amides patent
- cite prior art
- describe blood-brain barrier permeability assays
- discuss applicability of artificial membrane permeability assay
- introduce SwissADME tool
- describe BOILED-Egg method
- discuss improvement of cell permeability
- describe development of silicon-containing building blocks
- introduce tetrahydroquinoline derivatives
- discuss degenerate molecular shuttles
- describe sulfonamide derivatives
- discuss endocyclic restriction test
- introduce cyclopentane-1,3-dione isostere
- describe meta-substituent effects
- discuss aldosterone synthase inhibitors
- introduce substituted benzene fungicides
- describe cationic chalcone antibiotics
- describe molecular docking protocol
- discuss results of molecular docking
- introduce constrained amine analogues
- discuss potency of constrained amine analogues
- compare potency of constrained analogues to parent molecules
- describe small 4-alkyloxy-3-aminomethyl analogues
- illustrate binding of 25 to rnNOS
- describe binding of 25 to heNOS
- illustrate binding of 26 to rnNOS
- describe binding of 26 to heNOS
- illustrate binding of 27 to rnNOS
- describe binding of 27 to heNOS
- illustrate binding of 28 to rnNOS
- describe binding of 28 to heNOS
- describe unusual binding behavior of 31
- illustrate binding of 31 to heNOS
- describe structural features of 36
- illustrate binding of 36 to rnNOS
- describe binding of 36 to hnNOS
- describe structural features of 37
- illustrate binding of 37 to rnNOS
- describe binding of 37 to hnNOS
- provide experimental section
- synthesize tert-butyl (4-iodobenzyl)(methyl)carbamate
- synthesize (S,S)—N—(−1-(4-bromophenyl)propan-2-yl)-2-methylpro
- synthesize tert-butyl (S)-(1-(4-bromophenyl)propan-2-yl)carbamate
- provide NMR data for tert-butyl (S)-(1-(4-bromophenyl)propan-2-yl)carbamate
- conclude synthesis
- synthesize tert-Butyl (3-bromo-5-cyanobenzyl)carbamate
- synthesize tert-Butyl 4-bromoisoindoline-2-carboxylate
- synthesize (±)—N-(5-Bromo-2,3-dihydro-H-inden-1-yl)-2-methylpropane
- synthesize (±)-N-(6-Bromo-2,3-dihydro-H-inden-1-yl)-2-methylpropane
- synthesize (±)-tert-Butyl (5-Bromo-2,3-dihydro-1H-inden-1-yl
- synthesize (±)-tert-Butyl (6-bromo-2,3-dihydro-1H-inden-1-yl
- synthesize 2-(Bromomethyl)-1-fluoro-4-iodobenzene
- synthesize tert-Butyl (5-bromo-2-(trifluoromethyl)benzyl)carbamate
- synthesize 3-Bromo-2-ethylbenzaldehyde and 5-Bromo-2-ethylbenzaldehyde
- synthesize (5-Bromo-2-ethylphenyl)methanol
- synthesize 4-Bromo-2-(chloromethyl)-1-ethylbenzene
- describe NMR spectra of tert-Butyl (3-bromo-5-cyanobenzyl)carbamate
- describe NMR spectra of tert-Butyl 4-bromoisoindoline-2-carboxylate
- describe NMR spectra of (±)—N-(5-Bromo-2,3-dihydro-H-inden-1-yl)-2-m
- describe NMR spectra of (±)-N-(6-Bromo-2,3-dihydro-H-inden-1-yl)-2-m
- describe NMR spectra of (±)-tert-Butyl (5-Bromo-2,3-dihydro-1H-inden-
- describe NMR spectra of (±)-tert-Butyl (6-bromo-2,3-dihydro-1H-inden-
- describe NMR spectra of 2-(Bromomethyl)-1-fluoro-4-iodobenzene
- describe NMR spectra of tert-Butyl (5-bromo-2-(trifluoromethyl)benzyl)
- describe NMR spectra of 3-Bromo-2-ethylbenzaldehyde and 5-Bromo-2-ethyl
- describe NMR spectra of (5-Bromo-2-ethylphenyl)methanol
- describe NMR spectra of 4-Bromo-2-(chloromethyl)-1-ethylbenzene
- report physical properties of tert-Butyl (3-bromo-5-cyanobenzyl)carbamate
- report physical properties of tert-Butyl 4-bromoisoindoline-2-carboxylate
- report physical properties of 4-Bromo-2-(chloromethyl)-1-ethylbenzene
- describe compound synthesis
- detail Delépine reaction
- outline general procedure 1
- apply general procedure 1 to compound 85
- apply general procedure 1 to compound 86
- apply general procedure 1 to compound 94
- apply general procedure 1 to compound 97
- apply general procedure 1 to compound 100
- describe compound 103 synthesis
- detail general procedure 2
- apply general procedure 2 to compound 103
- apply general procedure 2 to compound 103 with 1-iodopropane
- apply general procedure 2 to compound 103 with 2-iodopropane
- report NMR data for compound 95
- report NMR data for compound 101
- report NMR data for compound 103
- synthesize compound 106
- synthesize compound 107
- synthesize compound 108
- synthesize compound 109
- synthesize compound 110
- synthesize compound 111
- characterize compound 106
- characterize compound 107
- characterize compound 108
- characterize compound 110
- characterize compound 111
- illustrate embodiments
- synthesize compound 112
- synthesize compound 113
- synthesize compound 114
- synthesize compound 115
- synthesize compound 116
- reference molecular force field
- reference generalized Born/volume integral implicit solvent model
- reference amber force field
- reference molecular operating environment
- reference human constitutive nitric oxide synthases
- reference optimization of blood-brain barrier permeability
- reference hydrophilic human neuronal nitric oxide synthase inhibitors
- reference automated design of ligands
- reference ring opening of cyclic sulfamidates
- reference process for preparation of pyrrolines
- reference halogenalkyl-substituted amides
- reference small organic molecule regulators

